此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)

2009年11月17日 更新者:Cordis Corporation

A Multicenter, Randomized Study of the Sirolimus-Eluting Bx VELOCITY® BALLOON Expandable Stent vs. Intravascular Brachytherapy in the Treatment of Patients With In-Stent Restenotic Coronary Artery Lesions

The main objective of this study is to demonstrate the superiority or non-inferiority of the sirolimus-eluting Bx VELOCITY® stent compared to intravascular brachytherapy in patients with in-stent restenotic native coronary artery lesions.

研究概览

研究类型

介入性

注册 (实际的)

384

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic Rochester

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • 1. The patient has an in-stent restenosis of > 50% (by subjective angiographic determination of the minimal luminal diameter compared to the distal reference diameter) within a native coronary artery which has previously undergone stent placement ( 4 weeks). Lesions must meet ISR Classification I-III.

    2. The patient has a history, signs of, or laboratory studies that suggest coronary ischemia attributable to the target stenosis. The diagnosis of angina pectoris is defined by Canadian Cardiovascular Society Classification (CCS I, II, III, or IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia;

    3. The study target lesion must be located in an in-stent restenotic native coronary artery measuring > 2.75mm and 3.5mm in diameter and > 15mm and 40mm in length to allow treatment with a maximum of three 18mm stents. The target lesion must have undergone coronary interventional treatment > 4 weeks previously. Patients with one or more prior percutaneous coronary interventions at the target lesion are acceptable candidates.

    4. The vessel 1cm distal to the target lesion is > 2.5mm in diameter;

    5. Ejection Fraction must be > 40%;

    6. The study target lesion cannot be located in a vessel containing a second lesion requiring treatment at the time of the procedure.

    7. Male or non-pregnant female patients > 18 years of age inclusive. NOTE: Females of child-bearing potential must have a negative pregnancy test (urine or serum) prior to enrollment and must use birth control for 6 months.

Exclusion Criteria:

  1. The study target lesion has definite or possible thrombus present by angiographic criteria.
  2. The patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK > 2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remain above normal at the time of treatment.
  3. Impaired renal function (Serum creatinine > 2.0mg/dl);
  4. The patient has unstable angina classified as Braunwald III B or C, or is having peri infarction angina.
  5. The left ventricular ejection fraction is < 40%.
  6. The target vessel has previously sustained a perforation.
  7. Totally occluded vessel (TIMI 0 level);
  8. Prior stent within 5mm of target lesion;
  9. There is a total occlusion of the restenosed-stent (ISR Classification IV) prior to the interventional procedure.
  10. Has an ostial target lesion;
  11. Significant (> 50%) in-stent restenoses proximal or distal to the target lesion that might require revascularization or impede runoff;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:1个
密码 Bx 速度
Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
有源比较器:2
Brachytherapy
Brachytherapy

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization at 9 months post-procedure.
大体时间:9 months post-procedure.
9 months post-procedure.

次要结果测量

结果测量
大体时间
术后 6 个月和 9 个月的靶病变血运重建 (TLR)。
大体时间:手术后 6 个月和 9 个月
手术后 6 个月和 9 个月
术后 6 个月和 9 个月的靶血管血运重建 (TVR)。
大体时间:手术后 6 个月和 9 个月
手术后 6 个月和 9 个月
Angiographic in-lesion and in-stent binary restenosis (³ 50% diameter stenosis) at 6 months post-procedure (by QCA).
大体时间:6 months post-procedure
6 months post-procedure
Post-procedure and six-month in-stent and in-lesion percent diameter stenosis (%DS) and late loss at 6 months post-procedure (by QCA) - [analysis at 6 months chosen so that results from the GAMMA Trial can be used].
大体时间:6 months post-procedure
6 months post-procedure
Post-procedure and six-month in-stent and in-lesion minimum lumen diameter (MLD) (by QCA).
大体时间:Post-procedure and at six-month
Post-procedure and at six-month
Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days and 6, 9, and 12-months, and 2, 3, 4, and 5 years post-proce
大体时间:30 days and 6, 9, and 12-months, and 2, 3, 4, and 5 years post-procedure
30 days and 6, 9, and 12-months, and 2, 3, 4, and 5 years post-procedure
Stent lumen and stent obstruction volume by intravascular ultrasound (IVUS) at post-procedure and six months in a subset of patients conducted at 5-7 investigational centers.
大体时间:post-procedure and six months
post-procedure and six months
Cost associated with the index hospitalization, length of stay, and repeat hospitalizations during the 12 mo post-procedure follow-up.
大体时间:12 mo post-procedure
12 mo post-procedure
Rate of late thrombosis
大体时间:Throughout study
Throughout study

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:David R. Holmes, Jr., MD、Mayo Clinic - Rochester, Minnesota

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2003年2月1日

初级完成 (实际的)

2005年1月1日

研究完成 (实际的)

2009年9月1日

研究注册日期

首次提交

2005年9月30日

首先提交符合 QC 标准的

2005年9月30日

首次发布 (估计)

2005年10月4日

研究记录更新

最后更新发布 (估计)

2009年11月19日

上次提交的符合 QC 标准的更新

2009年11月17日

最后验证

2009年11月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅